Effects of notoginsenoside R1 on CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 activities in rats by cocktail probe drugs

References

• Arold G, Donath F, Maurer A, et al. (2005). No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's Wort extract. Planta Med 71:331–7
   PubMed Web of Science ®Google Scholar
• Chan P, Thomas GN, Tomlinson B. (2002a). Protective effects of trilinolein extracted from Panax notoginseng against cardiovascular disease. Acta Pharmacol Sin 23:1157–62
   PubMed Web of Science ®Google Scholar
• Chan RY, Chen WF, Dong A, et al. (2002b). Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab 87:3691–5
   PubMed Web of Science ®Google Scholar
• Chavez ML, Jordan MA, Chavez PI. (2006). Evidence-based drug–herbal interactions. Life Sci 78:2146–57
   PubMed Web of Science ®Google Scholar
• Chen CH, Li XL, Zhang JX, et al. (2002). The effects of R1 and Rd extracted from Panax notoginseng saponins on microcirculation and blood coagulation. J West China Univ Med Sci 33:550–2
   Google Scholar
• Cicero AF, Vitale G, Savino G, et al. (2003). Panax notoginseng (Burk.) effects on fibrinogen and lipid plasma level in rats fed on a high-fat diet. Phytother Res 17:174–8
   PubMed Web of Science ®Google Scholar
• Coon MJ. (2005). Cytochrome P450: Nature's most versatile biological catalyst. Annu Rev Pharmacol Toxicol 45:1–25
   PubMed Web of Science ®Google Scholar
• De Smet PA. (2007). Clinical risk management of herb–drug interactions. Br J Clin Pharmacol 63:258–67
   PubMed Web of Science ®Google Scholar
• Deng GF, Wang DL, Meng MX, et al. (2009). Simultaneous determination of notoginsenoside R1, ginsenoside Rg1, Re, Rb1 and icariin in rat plasma by ultra-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:2113–22
   PubMed Web of Science ®Google Scholar
• Diani-Moore S, Papachristou F, Labitzke E, et al. (2006). Induction of CYP1A and cyp2-mediated arachidonic acid epoxygenation and suppression of 20-hydroxyeicosatetraenoic acid by imidazole derivatives including the aromatase inhibitor vorozole. Drug Metab Dispos 34:1376–85
   PubMed Web of Science ®Google Scholar
• Dou DQ, Xiang Z, Yang G, et al. (2011). Prediagnostic methods for the hemolysis of herbal medicine injection. J Ethnopharmacol 138:445–50
   PubMed Web of Science ®Google Scholar
• Feng L, Xiong Y, Cheng F, et al. (2004). Effect of ligustrazine on ischemia–reperfusion injury in murine kidney. Transplant Proc 36:1949–51
   PubMed Web of Science ®Google Scholar
• Foster BC, Vandenhoek S, Tang R, et al. (2002). Effect of several Chinese natural health products of human cytochrome P450 metabolism. J Pharm Pharm Sci 5:185–9
   PubMed Web of Science ®Google Scholar
• Fukami T, Nakajima M, Sakai H, et al. (2007). CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin and theophylline. Drug Metab Dispos 35:335–9
   PubMed Web of Science ®Google Scholar
• Gao LC, Zhang W, Liu ZQ, et al. (2012). Progress in clinical herb–drug interactions mediated by drug metabolism-related genes. Chin J Clin Pharmacol Ther 3:346–51
   Google Scholar
• He NW, Zhao Y, Guo L, et al. (2012). Antioxidant, antiproliferative, and pro-apoptotic activities of a saponin extract derived from the roots of Panax notoginseng (Burk.) F.H. Chen. J Med Food 15:350–9
   PubMed Web of Science ®Google Scholar
• Henderson GL, Harkey MR, Gershwin ME, et al. (1999). Effects of ginseng components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 65:209–14
   Web of Science ®Google Scholar
• Hu L, Xu W, Zhang X, et al. (2010). In-vitro and in-vivo evaluations of cytochrome P450 1A2 interactions with nuciferine. J Pharm Pharmacol 62:658–62
   PubMed Web of Science ®Google Scholar
• Izzo AA, Ernst E. (2001). Interactions between herbal medicines and prescribed drugs. Drugs 15:2163–75
   Web of Science ®Google Scholar
• Jia L, Zhao Y, Liang XJ. (2009). Current evaluation of the millennium phytomedicine-ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem 16:2924–42
   PubMed Web of Science ®Google Scholar
• Khanm AY, Preskorn SH. (2005). Examining concentration-dependent toxicity of clozapine: Role of therapeutic drug monitoring. J Psychiatr Pract 11:289–301
   PubMedGoogle Scholar
• Liu L, Shi R, Shi Q, et al. (2008). Protective effect of saponins from Panax notoginseng against doxorubicin-induced cardiotoxicity in mice. Planta Med 74:203–9
   PubMed Web of Science ®Google Scholar
• Liu SJ, Ju WZ, Chen WK, et al. (2010). Influence of xue-shuan-tong injection on P450 activities using a cocktail method. J Chin Pharm 45:115–18
   Google Scholar
• Moorthy B. (2008). The CYP1A Subfamily. In: Ioannides C, ed. Cytochromes P450 Role in the Metabolism and Toxicity of Drugs and other Xenobiotics. Cambridge: Royal Society of Chemistry, 101
   Google Scholar
• Netsch MI, Gutmann H, Schmidlin CB, et al. (2006). Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med 72:514–20
   PubMed Web of Science ®Google Scholar
• Ng TB. (2006). Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol 58:1007–19
   PubMed Web of Science ®Google Scholar
• Ning N, Dang X, Bai C, et al. (2012). Panax notoginsenoside produces neuroprotective effects in rat model of acute spinal cord ischemia-reperfusion injury. J Ethnopharmacol 139:504–12
   PubMed Web of Science ®Google Scholar
• Ou-Yang DS, Huang SL, Wang W, et al. (2000). Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 49:145–51
   PubMed Web of Science ®Google Scholar
• Park WH, Lee SK, Kim CH. (2005). A Korean herbal medicine, Panax notoginseng, prevents liver fibrosis and hepatic microvascular dysfunction in rats. Life Sci 76:1675–90
   PubMed Web of Science ®Google Scholar
• Ruan JQ, Leong WI, Yan R, et al. (2010). Characterization of metabolism and in vitro permeability study of notoginsenoside R1 from radix notoginseng. J Agric Food Chem 58:5570–6
   Web of Science ®Google Scholar
• Sharma A, Pilote S, Belanger PM, et al. (2004). A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: A pilot study. Br J Clin Pharmacol 58:288–97
   PubMed Web of Science ®Google Scholar
• Sun K, Wang CS, Guo J, et al. (2007). Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. Life Sci 8:509–18
   Web of Science ®Google Scholar
• Turpault S, Brian W, Van Horn R, et al. (2009). Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol 68:928–35
   PubMed Web of Science ®Google Scholar
• Ueng YF, Tsai CC, Lo WS, et al. (2010). Induction of hepatic cytochrome P450s by the herbal medicine Sophora flavescens extract in rats: Impact on the elimination of theophylline. Drug Metab Pharmacokinet 25:560–7
   PubMed Web of Science ®Google Scholar
• van Schaik, Ron HN. (2008). CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Update 3:77–98
   Web of Science ®Google Scholar
• Venkataramanan R, Komoroski B, Strom S. (2006). In vitro and in vivo assessment of herb drug interactions. Life Sci 78:2105–15
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Weemhoff JL, Bedir E, et al. (2004). Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 56:1039–44
   PubMed Web of Science ®Google Scholar
• Wang JB, Li SP, Chen JM, et al. (2007). Chemical characteristics of three medicinal plants of the Panax genus determined by HPLC-ELSD. J Sep Sci 30:825–32
   PubMed Web of Science ®Google Scholar
• Wang Y. (2012). Pharmacological effects of sanqi in blood system and new clinical application. Clin J Chin Med 4:45
   Google Scholar
• Xiao P, Zhou HH. (2008). Advance in cytochrome P450 1A2. J Cent South Univ (Med Sci) 5:456–60
   Google Scholar
• Yang ZG, Chen AQ, Yu SD, et al. (2005). Recent advances in the research of pharmacological activities of Panax notoginseng saponins. Chin J Veteran Drug 39:33–7
   Google Scholar
• Zhang HS, Wang SQ. (2006). Notoginsenoside R1-from Panax notoginseng inhibits TNF-alpha-induced PAI-1 production in human aortic smooth muscle cells. Vascul Pharmacol 44:224–30
   PubMed Web of Science ®Google Scholar
• Zhang HY, Jin JS. (2006). Progress of Panax notoginseng in pharmacological and clinical research for nephropathy. Med Recapitul 12:1466–7
   Google Scholar
• Zhang W, Chen G, Deng CQ. (2012). Effects and mechanisms of total Panax notoginseng saponins on proliferation of vascular smooth muscle cells with plasma pharmacology method. J Pharm Pharmacol 64:139–44
   PubMed Web of Science ®Google Scholar
• Zhang Z, Fasco MJ, Huang Z, et al. (1995). Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab Dispos 23:1339–46
   PubMed Web of Science ®Google Scholar
• Zhou S, Gao Y, Jiang W, et al. (2003). Interactions of herbs with cytochrome P450. Drug Meta Rev 35:35–98
   PubMed Web of Science ®Google Scholar